1. Home
  2. CACI vs MDGL Comparison

CACI vs MDGL Comparison

Compare CACI & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CACI
  • MDGL
  • Stock Information
  • Founded
  • CACI 1962
  • MDGL 2011
  • Country
  • CACI United States
  • MDGL United States
  • Employees
  • CACI N/A
  • MDGL N/A
  • Industry
  • CACI EDP Services
  • MDGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • CACI Technology
  • MDGL Health Care
  • Exchange
  • CACI Nasdaq
  • MDGL Nasdaq
  • Market Cap
  • CACI 7.3B
  • MDGL 6.8B
  • IPO Year
  • CACI 1979
  • MDGL N/A
  • Fundamental
  • Price
  • CACI $479.45
  • MDGL $290.96
  • Analyst Decision
  • CACI Buy
  • MDGL Strong Buy
  • Analyst Count
  • CACI 13
  • MDGL 10
  • Target Price
  • CACI $502.83
  • MDGL $420.63
  • AVG Volume (30 Days)
  • CACI 369.5K
  • MDGL 361.7K
  • Earning Date
  • CACI 04-23-2025
  • MDGL 05-01-2025
  • Dividend Yield
  • CACI N/A
  • MDGL N/A
  • EPS Growth
  • CACI 22.32
  • MDGL N/A
  • EPS
  • CACI 21.19
  • MDGL N/A
  • Revenue
  • CACI $8,361,975,000.00
  • MDGL $317,383,000.00
  • Revenue This Year
  • CACI $14.65
  • MDGL $264.55
  • Revenue Next Year
  • CACI $7.25
  • MDGL $67.21
  • P/E Ratio
  • CACI $22.56
  • MDGL N/A
  • Revenue Growth
  • CACI 14.16
  • MDGL N/A
  • 52 Week Low
  • CACI $318.60
  • MDGL $200.08
  • 52 Week High
  • CACI $588.26
  • MDGL $377.46
  • Technical
  • Relative Strength Index (RSI)
  • CACI 71.28
  • MDGL 40.85
  • Support Level
  • CACI $460.14
  • MDGL $280.00
  • Resistance Level
  • CACI $483.10
  • MDGL $307.54
  • Average True Range (ATR)
  • CACI 10.82
  • MDGL 15.97
  • MACD
  • CACI -1.12
  • MDGL -2.00
  • Stochastic Oscillator
  • CACI 91.09
  • MDGL 15.88

About CACI CACI International Inc.

CACI International Inc is an information solutions and services provider, offering information solutions and services to its customers. The company's primary customers are agencies and departments of the U.S. government, which account for the vast majority of the firm's revenue. It provides information solutions and services supporting national security missions and government modernization for intelligence, defense, and federal civilian customers. Some of the services provided by the company are functional software development, data, and business analysis, IT operations support, naval architecture, and life cycle support intelligence among others. The company's operating segments are; Domestic operations and International operations. It derives key revenue from the Domestic segment.

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Share on Social Networks: